Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesReviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.34 USD 0.00(0%)
Last update at 2026-11-12T15:36:00Z
VOLUME
51
Market Cap
6.29M

Momentum Score

…

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.34
Low
0.34
High
52 Week Price Range
0.26
Low
17.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.34
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.05
ROE
-176.60%
Net Debt
-14.03M
ROCE
-233.59%
Diluted EPS TTM
-1.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -19.85M -29.90M -39.24M -24.32M -8.52M
Net income -19.86M -29.92M -39.26M -24.34M -8.52M
Selling general administrative 8.49M 7.89M 8.08M 5.36M 5.25M
Reconciled depreciation - - - - 0.00M
Ebit - -60.68M -78.71M -24.31M -10.10M
Ebitda -19.83M -29.88M -39.21M -24.11M -10.10M
Depreciation and amortization - 30.80M 39.50M 0.19M 1.59M
Operating income -20.20M -30.80M -39.50M -24.31M -10.10M
Other operating expenses 20.20M 30.80M 39.50M 24.31M 10.10M
Interest expense 0.01M 0.02M 0.03M 0.18M 0.00M
Tax provision 0.02M 0.02M 0.02M 0.02M 0.01M
Interest income 0.31M 0.36M 0.50M 0.18M -
Net interest income 0.30M 0.34M 0.50M 0.18M -0.00M
Income tax expense 0.02M 0.02M 0.02M 0.02M 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 20.20M 30.80M 39.50M 24.31M 10.10M
Total other income expense net 0.35M 0.90M 0.26M -0.01M 1.59M
Net income from continuing ops -19.86M -29.92M -39.26M -24.34M -8.52M
Net income applicable to common shares - - - -24.34M -8.52M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 15.92M 15.50M 23.70M 18.92M 31.40M
Other current assets 0.66M 1.21M 0.33M 0.40M 1.72M
Total liab 7.28M 14.69M 17.98M 6.61M 2.72M
Total stockholder equity 8.65M 0.81M 5.72M 12.32M 28.69M
Other current liab 3.86M 7.86M - 2.52M 1.84M
Common stock 0.01M 0.00M - 0.00M 0.00M
Capital stock 0.01M 0.00M 0.00M 0.00M 0.00M
Retained earnings -184.14M -164.27M -134.35M -91.17M -66.83M
Other liab - - - 0.57M 0.37M
Other assets - - - 0.40M 1.72M
Cash 14.44M 13.48M 23.37M 18.52M 29.69M
Total current liabilities 7.28M 14.60M 17.18M 6.04M 2.34M
Net debt -14.03M -13.02M - -18.52M -29.69M
Short term debt 0.41M 0.46M - - -
Short long term debt 0.41M 0.46M - - -
Short long term debt total 0.41M 0.46M - - -
Other stockholder equity 192.77M 165.08M - 103.49M 95.52M
Total current assets 15.10M 14.68M 23.70M 18.92M 31.40M
Net tangible assets - - - 12.32M 28.69M
Accounts payable 3.01M 6.28M 3.85M 3.52M 0.51M
Non currrent assets other 0.82M 0.82M - - -
Non current assets total 0.82M 0.82M 0.00M 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Change to liabilities - - - 3.01M -0.50M
Net borrowings -0.05M 0.46M 0.00M - -
Total cash from financing activities 25.56M 23.65M 33.17M 7.79M 31.60M
Change to operating activities - - - 2.00M -0.20M
Net income -19.86M -29.92M -39.26M -24.34M -8.52M
Change in cash 0.96M -9.89M 4.85M -11.17M 20.93M
Begin period cash flow 13.48M 23.37M 18.52M 29.69M 8.76M
End period cash flow 14.44M 13.48M 23.37M 18.52M 29.69M
Total cash from operating activities -24.59M -33.54M -28.32M -18.96M -10.67M
Issuance of capital stock 18.63M 23.19M 27.49M 7.77M 31.50M
Depreciation - - - - 0.00M
Other cashflows from financing activities 25557078.44M 0.00M 5.68M 0.02M 0.10M
Change to netincome - - - 0.37M -1.44M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -6.87M -4.54M 7.28M 5.01M -0.70M
Stock based compensation 2.23M 1.63M 3.41M 0.18M 0.11M
Other non cash items -0.09M -0.72M 0.24M 0.19M -1.55M
Free cash flow -24.59M -33.54M -28.32M -18.96M -10.67M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RVPH
Reviva Pharmaceuticals Holdings Inc.		 -
-%		 0.34 - - - 0.41 -6.00
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

10080 N. Wolfe Road, Cupertino, CA, United States, 95014

408 501 8881

https://www.revivapharma.com

14

Name Title Year Born
Dr. Laxminarayan Bhat Ph.D. Founder, CEO, Pres & Director 1965
Mr. Narayan Prabhu Chief Financial Officer 1972
Dr. Laxminarayan Bhat Ph.D. Founder, CEO, President & Director 1965
Dr. Laxminarayan Bhat Ph.D. Founder, CEO, President & Director 1966
Mr. Narayan Prabhu CFO, Treasurer & Secretary 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…